Reducing opioid prescribing after ambulatory breast reconstruction surgery.
J Surg Oncol
; 128(8): 1235-1242, 2023 Dec.
Article
em En
| MEDLINE
| ID: mdl-37653689
ABSTRACT
BACKGROUND:
The lack of evidence-based guidelines for postoperative opioid prescriptions following breast reconstruction contributes to a wide variation in prescribing practices and increases potential for misuse and abuse.METHODS:
Between August and December 2019, women who underwent outpatient breast reconstruction were surveyed 7-10 days before (n = 97) and after (n = 101) implementing a standardized opioid prescription reduction initiative. We compared postoperative opioid use, pain control, and refills in both groups. Patient reported outcomes were compared using the BREAST-Q physical wellbeing of the chest domain and a novel symptom Recovery Tracker.RESULTS:
Before changes in prescriptions, patients were prescribed a median of 30 pills and consumed three pills (interquartile range [IQR 1,9]). After standardization, patients were prescribed eight pills and consumed three pills (IQR 1,6). There was no evidence of a difference in the proportion of patients experiencing moderate to very severe pain on the Recovery Tracker or in the early BREAST-Q physical wellbeing of the chest scores (p = 0.8 and 0.3, respectively).CONCLUSION:
Standardizing and reducing opioid prescriptions for patients undergoing reconstructive breast surgery is feasible and can significantly decrease the number of excess pills prescribed. The was no adverse impact on early physical wellbeing, although larger studies are needed to obtain further data.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dor Pós-Operatória
/
Mamoplastia
/
Procedimentos de Cirurgia Plástica
/
Analgésicos Opioides
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article